TAG-72 expression and its role in the biological evaluation of human colorectal cancer

Anticancer Research

Volumn 16, Issue 4 B, 1996, Pages 2141-2148

  Guadagni, Fiorella ^a   Roselli, Mario ^b   Cosimelli, Maurizio ^a   Ferroni, Patrizia ^c   Spila, Antonella ^a   Cavaliere, Francesco ^a   Arcuri, Raffaella ^a   Carlini, Sandro ^a   Mariotti, Sabrina ^c   Gandolfo, Giuseppe M ^a   Casciani, Carlo U ^b   Greiner, John W ^d   Schlom, Jeffrey ^d  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Colorectal cancer; Human; TAG 72

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; TUMOR ANTIGEN;

ARTICLE; BODY FLUID; CANCER STAGING; COLORECTAL CARCINOMA; HUMAN; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; LONGITUDINAL STUDY; PRIORITY JOURNAL; TUMOR DIFFERENTIATION;

ANTIGENS, NEOPLASM; COLORECTAL NEOPLASMS; GLYCOPROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; TUMOR MARKERS, BIOLOGICAL;

EID: 9444298412     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (71)

1. Colcher D, Horan Hand P, Nuti M and Schlom J: A spectrum of monoclonal antibodies reactive with human mammary tumor cells. Proc Natl Acad Sci USA 78: 3199-3203, 1981.
2. Johnson VG, Schlom J, Paterson AJ, Bennett J, Magnani JL and Colcher D: Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3. Cancer Res 46: 850-857, 1986.
3. Muraro R, Kuroki D, Wunderlich D et al: Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor associated glycoprotcin-72 antigen. Cancer Res 48: 4588-4596, 1988.
4. Colcher D, Minelli MF, Roselli M, Muraro R, Simpson-Milenic D and Schlom J: Radioimmunolocalization of human carcinoma xenografts with B72.3 second generation monoclonal antibodies. Cancer Res 48: 4597-4603, 1998.
5. Sheer DG , Schlom J and Cooper HL: Purification and composition of the human tumor-associated glycoprotein (TAG-72) defined by monoclonal antibodies CC49 and B72.3. Cancer Res 48: 6811-6818, 1988.
6. Katari RS, Fernsten PD and Schlom J: Characterization of the shed form of the human tumor-associated glycoprotein (TAG-72) from serous effusions of patients with different types of carcinomas. Cancer Res 50: 4885-4890, 1990.
7. Thor A, Ohuchi N, Szpak CA, Johnston WW and Schlom J: Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3. Cancer Res 46: 3118-3124, 1986.
8. Molinolo A, Simpson JF, Thor A and Schlom J: Enhanced tumor binding using immunohistochemical analyses by second generation anti-tumor-associated glycoprotein- 72 monoclonal antibodies versus monoclonal antibody B72.3 in human tissue. Cancer Res 50: 1291-1298, 1990.
9. Thor A, Gorstein F, Ohuchi N, Szpak CA. Johnston WW and Schlom J: Tumor-associated glycoprotein-72 (TAG-72) in ovarian carcinomas defined by monoclonal antibody H72.3. J Natl Cancer Inst 76: 995-1003, 1986.
10. Ohuchi N, Simpson JF, Colcher D and Schlom J: Complementation of anti-CEA and anti-TAG-72 monoclonal antibodies in reactivity to human gastric adenocarcinomas. Int J Cancer 40: 726-733, 1987.
11. Thor A, Viglione MJ, Muraro R, Ohuchi N, Schlom J and Gorstein F: Monoclonal antibody B72.3 reactivity with human endometrium: A study of normal and malignant tissues. Int J Gyn Path 6: 235-247, 1987.
12. Gero EJ, Colcher D, Ferroni P et al: The CA 72-4 radioimmunoassay for the detection of the TAG-72 carcinoma associated antigen in serum of patients. J. Clin Lab Analysis 3: 360-369, 1989.
13. Ohuchi N, Takahashi K, Matoba N et al: Comparison of serum assay for TAG-72, CA 19-9, and CEA in gastrointestinal carcinoma patients. Jpm J Clin Oncol 19: 242-248, 1989.
14. Ohuchi N, Gero E, Mon S et al: Clinical evaluation of CA 72-4 immunoradiometric assay for serum TAG-72 antigen in patients with carcinoma. J Tumor Marker Oncology 5: 1-10, 1990.
15. Guadagni F, Roseili M, Amato T, Cosimelli M, Mannella E, Perri P, Abbolito MR, Cavalierc R, Colcher D, Greiner JW and Schlom J: Tumor-associated glycoprotein-72 (TAG-72) serum levels complement carcinoembryonic antigen levels in monitoring patients with gastrointestinal carcinoma: A longitudinal study. Cancer 68: 2443-2450, 1991.
16. Guadagni F, Roselli M, Ferroni P, Amato T, Colcher D, Greiner JW and Schlom J: Clinical evaluation of the new tumor marker TAG-72. Anticancer Res 11: 1389-1394, 1991.
17. Guadagni F, Roselli M, Amato T, Cosimelli M, Mannella E, Tedesco M, Grassi A, Casale V, Cavaliere F, Greiner JW and Schlom J: Clinical evaluation of serum tumor-associated glycoprotein-72 as a novel tumor marker for colorectal cancer patients. J Surg Oncol 2: 16-20, 1991.
18. Guadagni F, Roselli M, Amato T, Cosimelli M, Mannella E, Tedesco M, Cavaliere F, Grassi A, Abbolito MR, Greiner JW and Schlom J: TAG-72 (CA 72-4 assay) as a complementary scrum tumor antigen to CEA in monitoring colorectal cancer patients. Cancer 72: 2098-2106, 1993.
19. Guadagni F, Roselli M, Cosimelli M, Spila A, Cavaliere F, Arcuri R, Abbolito MR, Greiner JW and Schlom J: Biologic evaluation of tumor-associated glycoprotein-72 and carcinoembryonic antigen expression in colorectal cancer, Part 1. Dis Colon Rectum 37: S16-S23, 1994.
20. Nuti M, Teramoto YA, Mariani-Costantini R, Horan Hand P, Colcher D and Schlom J: A monoclonal antibody (B72.3) defines pattern of distribution of a novel tumor-associated antigen in human mammary carcinoma cell populations. Int J Cancer 29: 539-45, 1982.
21. Sttamignoni D, Bowen R, Atkinson B and Schlom J: Differential reactivity of monoclonal antibodies with human colon adenocarcinomas and adenomas, Int J Cancer 31: 543-52, 1983.
22. Xu M., Real FX., Welt S., Schussler MH, Oettgen HF and Old LJ: Expression of TAG-72 in normal colon, transitional mucosa, and colon cancer. Int J Cancer 44: 985-989, 1989.
23. Wolf RC, Salem RR, Sears HF et al: The expression of colorectal carcinoma associated antigens in the normal colon: An immunohistochemical analysis of regional distribution. Am J Pathol 135: 111-119, 1989.
24. Simpson JF, Primus FJ and Schlom J: Complementation of expression of carcinoembryonic antigen and tumor associated glycoprotein-72 (TAG-72) in human colon adenocarcinomas. Int J Biol Markers 6: 83-90, 1991.
25. Au FC, Stein B, Tang CK: Carcinoembryonic antigen levels in colonic lesion. Am J Surg 151: 61-64, 1986.
26. Enblad P., Busch C, Carlsson E. et al: The adenomacarcinoma sequence in rectal adenomas. Support by expression of blood group substances and carcinoma antigen. Am J Pathol 89: 121-130, 1988.
27. O'Brien MJ, Zamcheck N, Burke B et al: Immunocytochemical localization of carcinoembryonic antigen in benign and malignant colorectal tissues. Assessment of diagnostic value. Am J Clin Pathol 75: 283-290, 1981.
28. Wolf RC, D'Emilia JC, Salem RR, DeCoste D, Sears HF, Gottlieb LS and Steele GD Jr: Detection of the tumor associated glycoprotein (TAG-72) in premalignant lesions of the colon. J Natl Cancer Inst 81: 1913-1917, 1989.
29. Levallen EC and Carr DT: Pleural effusion: a statistical study of 436 patients. N Eng J Med 252: 79-83, 1955.
30. Johnston WW: The malignant pleural effusion. Cancer 56: 905-909, 1985.
31. Johnson WD: The cytologic diagnosis of cancer in serous effusions. Acta Cytol 10: 161-172, 1966.
32. Lopes Cardozo PL: A critical evaluation of 3,000 cytologic analyses of pleural fluid, ascitic fluid, and peritoneal fluid. Acta Cytol. 10: 455-460, 1966.
33. Dekker A and Bupp PA: Cytology of serous effusions, An investigation into the usefulness of cell blocks vs smear. Am J Clin Pathol 70: 855-860, 1978.
34. Dines DE, Pierre RV and Franzen SJ: The value of cells in the pleural fluid in the differential diagnosis. Mayo Clin Proc 50: 571-572, 1975.
35. Thor A, Simpson J, Ohuchi N, Horan Hand P, Szpak CA, Johnston WW and Schlom J: Monoclonal antibodies and human carcinomas: Diagnostic and experimental applications. In "Advances in Immunocytochemistry". Ed by Ronald A. DeLellis, Raven Press, New York, pp. 165-190, 1988
36. Johnston WW, Szpak CA, Lottich SC, Thor A, Schlom J. Use of a monoclonal antibody (B72.3) as an immunocytochemical adjunct to diagnosis of adenocarcinomas in human effusions. Cancer Res 45: 1894-900, 1985.
37. Szpak CA, Johnston WW, Roggli V et al: The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody (B72.3). Am J Pathol 122: 252-260, 1986.
38. Martin SE, Moshiri S, Thor A and Schlom J: Identification of adenocarcinoma in cytospin preparations of effusions using monoclonal antibody B72.3. Am J Clin Pathol 86: 10-18, 1986.
39. Mottolese M, Venturo I, Perrone Donnorso R, Gallo Curcio C, Rinaldi M and Natali PG: Use of selected combination of monoclonal antibodies to tumor associated antigens in the diagnosis of neoplastic effusions of unknown origin. Eur J Cancer Clin Oncol 24: 1277-1284, 1988.
40. Szpak CA, Johnston WW, Lottich SC, Kufe D, Thor A and Schlom J: Patterns of reactivity of four novel monoclonal antibodies (B72.3, DF3, B1.1 and B6.2) with cells in human malignant and benign effusions. Acta Cytol 28: 356-367, 1984.
41. Johnston WW, Szpak CA, Lottich SC, Thor A and Schlom J: Use of a monoclonal antibody as a novel immunohistochemical adjunct for the diagnosis of carcinomas in fine needle aspiration biopsies. Hum Pathol 17: 501-513, 1986.
42. Johnston WW, Szpak CA, Thor A, Simpson JF and Schlom J: Applications of immunocytochemistry to clinical cytology. Cancer Invest 5: 593-611, 1987.
43. Mezger J, Permanetter W, Gerbes AL, Wilmanns W and Lamerz R: Tumor associated antigens in diagnosis of serous effusions. J Clin Pathol 41: 633-643, 1988.
44. Nystrom JS, Dyce B, Wada J, Bateman JR and Haverback B: Carcinoembryonic antigen titers on effusion fluid. A diagnostic tool? Arc Intern Med 137: 875-879, 1977.
45. Pinto MM, Bernstein LH, Brogan DA and Criscuolo EM: Carcinoembryonic antigen in effusions. A diagnostic adjunct to cytology. Acta Cytologica 31: 113-118, 1987.
46. Ferroni P, Szpak C, Greiner JW et al: CA 72-4 radioimmunoassay in the diagnosis of malignant effusions. Comparison of various tumor markers. Int J Cancer 46: 445-451, 1990.
47. Paterson AJ, Schlom J, Sears HS et al: A radioimmunoassay for the detection of a human tumor-associated glycoprotein (TAG-72) using monoclonal antibody B72.3. Int J Cancer 37: 659-666, 1986.
48. Klug TL, Sattler MA, Colcher D and Schlom J: Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 72) on a novel pancarcinoma antigen (TAG-72). Int J Cancer 38: 661-669, 1986.
49. Wanebo HJ, Rao B, Pinsky CM et al: Preoperative carcinoembryonic antigen levels as a prognostic indicator of colorectal cancer. N Engl J Med 299: 448-451, 1978.
50. Sikorska H, Shuster J and Gold P: Clinical applications of carcinoembryonic antigen. Cancer Detect Prev 12: 321-355, 1988.
51. Sears HF, Herlyn M, Del Villano B, Steplewski Z and Koprowski H: Monoclonal antibody detection of a circulating tumor associated antigen. II. A longitudinal evaluation of patients with colorectal cancer. J Clin Immunol 2: 141-149, 1982.
52. Mughal AW, Hortobagyi GN, Fritsche HA, Buzdar AU, Yap HY and Blumenschein GR: Serial plasma carcinoembryonic antigen measurements during treatment of metastatic breast cancer. JAMA 249: 1881-1886, 1983.
53. Mach JP, Jaeger P and Bertholet MM: Detection of recurrence of large-bowel carcinoma by radioimmunoassay of circulating carcinoembryonic antigen (CEA). Lancet 7: 535-540, 1974.
54. Martin EW Jr, Cooperman M, Carly LC and Minton JP: Sixty second-look procedures indicate primarily by rise in serial carcinoembryonic antigen. J Surg Res 28: 389-394, 1980.
55. Szymendera JJ, Nowacki MP, Szawlowski AW and Kamiska JA: Predictive value of plasma CEA levels: preoperative prognosis and postoperative monitoring of patients with colorectal carcinoma. Dis Colon Rectum 25: 46-52, 1982.
56. Wood CB, Ratcliffe JG, Burt RW, Malcolm AJH and Blumgast LH: The clinical significance of the pattern of elevated serum carcinoembryonic antigen (CEA) levels in recurrent colorectal cancer. Br J Surg 67: 47-48, 1980.
57. Schlom J, Colcher D, Roselli M et al: Tumor targeting with monoclonal antibody B72.3. Nucl Med Biol 16(2): 137-142, 1989.
58. Esteban JM, Colcher D, Sugarbaker P et al: Quantitative and qualitative aspects of radiolocalization in colon cancer patients of intravenously administered MAh B72.3. Int J Cancer 39: 50-59, 1987.
59. Colcher D, Esteban JM, Carrasquillo JA et al: Complementation of intracavitary and intravenous administration of a monoclonal antibody (B72.3) in patients with carcinoma. Cancer Res 47: 4218-4224, 1987.
60. Sikle-Santanello BJ, O'Dwyer PJ, Mojzisik C et al: Radioimmunoguided surgery using the monoclonal antibody B72.3 in colorectal tumors. Dis Colon Rectum 30: 761-764, 1987.
61. Prehn RT: Analysis of antigen heterogeneity within individual 3-methyl-cholantrene-induced mouse sarcomas. J Natl Cancer Inst 45: 1039-44, 1970.
62. Miller FR and Heppner GH: Immunologic heterogeneity of tumor cell subpopulations from a single mouse mammary tumor. J Natl Cancer Inst 63: 1457-1461, 1979.
63. Horan-Hand P, Nuti M, Colcher D and Schlom J: Definition of antigenic heterogeneity and modulation among mammary carcinoma cell populations using monoclonal antibodies to tumor-associated antigens. Cancer Res 43: 728-735, 1983.
64. Heron I, Hokland M and Berg K: Enhanced expression of 132-microglobulin and HLA antigens on human lymphoid cells by interferon. Proc Natl Acad Sci USA 5: 6215-6219, 1978.
65. Wallach D, Fellous M and Revel M: Preferential effect of gamma interferon on the synthesis of HLA antigens and their mRNAs. Nature 299: 833-836, 1982.
66. Greiner JW, Horan-Hand P, Noguchi P, Fisher, PB, Pestka S and Schlom J: Enhanced expression of surface tumor-associated antigens on human breast and colon tumor cells after recombinant human leukocyte α-interferon treatment. Cancer Res 44: 3208-3213, 1984.
67. Greiner JW, Guadagni F, Noguchi P et al: Recombinant interferon enhances monoclonal antibody targeting of carcinoma lesions in vivo. Science 235: 895-899, 1987.
68. Guadagni F, Schlom J, Pothen S, Pestka S and Greiner JW: Parameters involved in the enhancement of monoclonal antibody targeting in vivo with recombinant interferon. Cancer Immunol Immunother 26: 222-230, 1988.
69. Guadagni F, Schlom J, Johnston W et al: Selective interferon-induced enhancement of tumor-associated antigens on a spectrum of freshly isolated human adenocarcinoma cells. J Natl Cancer Inst 81: 502-512, 1989.
70. Greiner JW, Guadagni F, Goldstein D, Smalley RV, Borden E, Simpson JF, Molinolo A and Schlom J: Intraperitoneal administration of interferon-gamma to carcinoma patients enhances expression of tumor-associated glycoprotein-72 and carcinoembryonic antigen on malignant ascites cell. J Clin Oncol 10: 735-746, 1992.
71. 131I-labeled monoclonal antibodies prepared against human milk fat globule. Cancer Res 48: 4664-4672, 1988.